Clinical Trial Update: NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for an NMDA-enhancing agent in mild cognitive impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Mild Cognitive Impairment | Phase 2 | Status: COMPLETED